Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab + cemdisiran versus cemdisiran alone in geographic atrophy secondary to age-related macular degeneration
2023-509547-27-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in age-related macular degeneration (AMD) comparing Pozelimab + cemdisiran, Cemdisiran alone and Placebo (3 arms). Primary endpoint: Growth rate of total GA lesion area. Planned start Feb 2025; status: authorised.
02
Drugs
pozelimabcemdisiran
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2023-509547-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509547-27-00.